Cargando…

CiPA-compliant assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine

Detalles Bibliográficos
Autores principales:	Amuzescu, Bogdan, Thomet, Urs, Knott, Thomas, Mann, Stefan, Radu, Beatrice Mihaela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483628/ http://dx.doi.org/10.1016/j.vascn.2021.107039

Ejemplares similares

Assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine using the CiPA concept
por: Thomet, Urs, et al.
Publicado: (2021)

Introduction to in silico model for proarrhythmic risk assessment under the CiPA initiative
por: Park, Jin-Sol, et al.
Publicado: (2019)

Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative
por: Li, Zhihua, et al.
Publicado: (2018)

In silico assessment on TdP risks of drug combinations under CiPA paradigm
por: Qauli, Ali Ikhsanul, et al.
Publicado: (2023)

Five years of the CiPA project (2013–2018): what did we learn?
por: Yim, Dong-Seok
Publicado: (2018)

General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy
por: Li, Zhihua, et al.
Publicado: (2019)

Applying CiPA paradigm for assessing proarrhythmia risk of Covid-19 current off-label used therapies
por: Delaunois, Annie, et al.
Publicado: (2021)

Assessment of the proarrhythmic effects of repurposed antimalarials for COVID-19 treatment using a comprehensive in vitro proarrhythmia assay (CiPA)
por: Yoon, Seung-Hyun, et al.
Publicado: (2023)

Usefulness of Bnet, a Simple Linear Metric in Discerning Torsades De Pointes Risks in 28 CiPA Drugs
por: Han, Sungpil, et al.
Publicado: (2019)

Mechanistic Model‐Informed Proarrhythmic Risk Assessment of Drugs: Review of the “CiPA” Initiative and Design of a Prospective Clinical Validation Study
por: Vicente, Jose, et al.
Publicado: (2017)

Testing the nonclinical Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm with an established anti‐seizure medication: Levetiracetam case study
por: Delaunois, Annie, et al.
Publicado: (2023)

Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19
por: Delaunois, Annie, et al.
Publicado: (2021)

Assessment of Multi‐Ion Channel Block in a Phase I Randomized Study Design: Results of the CiPA Phase I ECG Biomarker Validation Study
por: Vicente, Jose, et al.
Publicado: (2019)

Mitral Valve Prolapse: An Innocent Bystander or Proarrhythmogenic Anomaly?
por: Shukla, Raj, et al.
Publicado: (2021)

Cross-Site Reliability of Human Induced Pluripotent stem cell-derived Cardiomyocyte Based Safety Assays Using Microelectrode Arrays: Results from a Blinded CiPA Pilot Study
por: Millard, Daniel, et al.
Publicado: (2018)

Pharmacology of Chloroquine and Hydroxychloroquine
por: Browning, David J.
Publicado: (2014)

Chloroquine/hydroxychloroquine overdose
por: McKeever, Rita
Publicado: (2020)

Proarrhythmogenic effects of lamotrigine during ajmaline testing for Brugada syndrome
por: Leong, Kevin M.W., et al.
Publicado: (2017)

Chloroquine and hydroxychloroquine for cancer therapy
por: Manic, Gwenola, et al.
Publicado: (2014)

Chloroquine, hydroxychloroquine and COVID-19
por: Erickson, T. B., et al.
Publicado: (2020)

Reported ADRs with chloroquine or hydroxychloroquine
Publicado: (2021)

Nanomedicine Reformulation of Chloroquine and Hydroxychloroquine
por: Stevens, David M., et al.
Publicado: (2020)

Hydroxychloroquine- and chloroquine-related cardiovascular events
Publicado: (2020)

Chloroquine and hydroxychloroquine in the context of COVID-19
por: Shukla, Ashutosh M, et al.
Publicado: (2020)

Chloroquine or hydroxychloroquine for prophylaxis of COVID-19
por: Principi, Nicola, et al.
Publicado: (2020)

Hydroxychloroquine or chloroquine +/- azithromycin: heart disorders
Publicado: (2022)

Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine
por: Gies, Vincent, et al.
Publicado: (2020)

Brief Review of Chloroquine and Hydroxychloroquine Toxicity and Management
por: Lebin, Jacob A., et al.
Publicado: (2020)

Risks of chloroquine or hydroxychloroquine use for COVID-19
Publicado: (2020)

COVID-19 and Chloroquine/Hydroxychloroquine: is there Ophthalmological Concern?
por: Marmor, Michael F.
Publicado: (2020)

COVID-19 and Chloroquine/Hydroxychloroquine: Is There Ophthalmological Concern?
por: Marmor, Michael F.
Publicado: (2020)

Antimalarials (chloroquine and hydroxychloroquine) in the COVID-19 pandemic()
por: Jáuregui, Edwin
Publicado: (2021)

Nephrotoxicity of Chloroquine and Hydroxychloroquine in COVID-19 Patients
por: Mahmoudi, Javad, et al.
Publicado: (2021)

Chloroquine and Hydroxychloroquine: Efficacy in the Treatment of the COVID-19
por: Ho, Tzu-Chuan, et al.
Publicado: (2021)

The Ototoxicity of Chloroquine and Hydroxychloroquine: A Systematic Review
por: Fernandes, Carolina Pereira, et al.
Publicado: (2022)

Chloroquine or hydroxychloroquine for prevention and treatment of COVID‐19
por: Singh, Bhagteshwar, et al.
Publicado: (2021)

Evidence for Chloroquine/Hydroxychloroquine in the Treatment of COVID-19
por: Shetty, Rajesh M, et al.
Publicado: (2021)

Cardiotoxicity of chloroquine and hydroxychloroquine through mitochondrial pathway
por: Seydi, Enayatollah, et al.
Publicado: (2023)

Chloroquine and Hydroxychloroquine in the Treatment of Dry Eye Disease
por: Prinz, Julia, et al.
Publicado: (2023)

Cost-effectiveness of the hospital nutrition screening tool CIPA
por: Suárez-Llanos, José Pablo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_32fmvvrtlt0h40e728vf8uch8s